We provide you with 20 years of free, institutional-grade data for ENTA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ENTA. Explore the full financial landscape of ENTA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Kowalsky Matthew Paul | Sale | -1,902 | $14.25 | $27,104 | 2026-02-13 |
| Kowalsky Matthew Paul | Grant, award...etc | 5,493 | 2026-02-13 | ||
| Luu Brendan | Sale | -3,257 | $14.25 | $46,412 | 2026-02-13 |
| Luu Brendan | Grant, award...etc | 6,562 | 2026-02-13 | ||
| Kieffer Tara Lynn | Sale | -3,257 | $14.25 | $46,412 | 2026-02-13 |
| Kieffer Tara Lynn | Grant, award...etc | 6,562 | 2026-02-13 | ||
| Rottinghaus Scott T. | Sale | -3,413 | $14.25 | $48,635 | 2026-02-13 |
| Rottinghaus Scott T. | Grant, award...etc | 6,875 | 2026-02-13 | ||
| Or Yat Sun | Sale | -3,413 | $14.25 | $48,635 | 2026-02-13 |
| Or Yat Sun | Grant, award...etc | 6,875 | 2026-02-13 | ||
| Luly Jay R. | Sale | -6,155 | $14.25 | $87,709 | 2026-02-13 |
| Luly Jay R. | Grant, award...etc | 20,000 | 2026-02-13 | ||
| Kieffer Tara Lynn | Sale | -2,106 | $14.23 | $29,968 | 2025-12-05 |
| Or Yat Sun | Sale | -2,390 | $14.23 | $34,010 | 2025-12-05 |
| Luly Jay R. | Sale | -4,743 | $14.23 | $67,493 | 2025-12-05 |
| Rottinghaus Scott T. | Sale | -798 | $14.23 | $11,356 | 2025-12-05 |
| Capps Kathleen S. | Sale | -323 | $14.23 | $4,596 | 2025-12-05 |
| Luu Brendan | Sale | -1,394 | $14.23 | $19,837 | 2025-12-05 |
| Trout Harry R. III | Sale | -542 | $14.23 | $7,713 | 2025-12-05 |
| Capps Kathleen S. | Sale | -292 | $14.12 | $4,123 | 2025-12-03 |
| Luu Brendan | Sale | -498 | $14.12 | $7,032 | 2025-12-03 |
| Trout Harry R. III | Sale | -485 | $14.12 | $6,848 | 2025-12-03 |
| Kieffer Tara Lynn | Sale | -753 | $14.12 | $10,632 | 2025-12-03 |
| Or Yat Sun | Sale | -753 | $14.12 | $10,632 | 2025-12-03 |
| Luly Jay R. | Sale | -1,885 | $14.12 | $26,616 | 2025-12-03 |
The information provided in this report about ENTA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Enanta Pharmaceuticals, Inc(NASDAQ:ENTA) 
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovi...
Website: http://www.enanta.com
Founded: 1995
Full Time Employees: 141
Sector: Healthcare
Industry: Biotechnology